IDH1 and acute myeloid leukemia: In particular, about 20% of adult AML patients present early mutations of IDHs [37,41], which are associated with an about 100-fold increase in the levels of 2-HG compared to wild-type IDHs [33,34,42,43], suggesting 2-HG as playing a role as a marker of tumor-associated IDH mutations [42].